Clinical DevelopmentEarly signs of efficacy and favorable safety profiles will facilitate further development of RP-1664 and RP-3467.
Financial StabilityThe company has a cash runway guidance through 2027, supported by $109.5 million in cash, equivalents, and marketable securities.
Strategic PartnershipsRepare announced entry into a worldwide, exclusive license agreement with Debiopharm around lunreserb, yielding $10M upfront and up to $257M in potential milestones.